Management of Patients With Nonmetastatic Prostate Cancer

Presented by:
Julio M. Pow-Sang
Search for other papers by Julio M. Pow-Sang in
Current site
Google Scholar
PubMed Close
 MD
Volume/Issue:
Volume 20: Issue 5.5
Online Publication Date:
02 Jun 2022
DOI:
https://doi.org/10.6004/jnccn.2022.5012
Restricted access

Localized prostate cancer is a heterogeneous disease. However, some diagnostic features are helpful in categorizing patients into risk groups for adverse outcomes, such as pathology, imaging, and genetic profiling. Risk‐specific management options, including active surveillance, can be tailored to individual patients based on their risk profile. Clinicians should discuss the risks and benefits of each of these options with patients for informed decision-making.

Disclosures: Dr. Pow-Sang has disclosed serving as a scientific advisor for Lantheus.

Correspondence: Julio M. Pow-Sang, MD, Department of Genitourinary Oncology, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612. Email: julio.powsang@moffitt.org
  • Collapse
  • Expand
Print ISSN:
1540-1405
Online ISSN:
1540-1413
Publisher:
National Comprehensive Cancer Network
Cover Journal of the National Comprehensive Cancer Network
  • 1.

    Centers for Disease Control and Prevention. U.S. Cancer Statistics Data Visualizations Tool, based on 2020 submission data (1999-2018). Accessed February 13, 2022. Available at: www.cdc.gov/cancer/dataviz

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Schaeffer EM, Srinivas S, Antonarakis ES, et al. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 3.2022. Accessed February 13, 2022. Available at NCCN.org

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Weinreb JC, Barentsz JO, Choyke PL, et al. PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. Eur Urol 2016;69:16–40.

  • 4.

    Pienta KJ, Gorin MA, Rowe SP, et al. A phase 2/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET/CT with 18 F-DCFPyL in prostate cancer patients (OSPREY). J Urol 2021;206:52–61.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
Copyright:
Copyright © 2022 by the National Comprehensive Cancer Network 2022
Page Numbers:
4
Article Category:
Research Article
Print Publication Date:
01 May 2022
Online Publication Date:
02 Jun 2022

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 3056 360 26
PDF Downloads 1828 219 30
EPUB Downloads 0 0 0